Analysis of social class by LCA in patients with schizophrenia: Change in psychopathology after 12- Rmonth of treatment

Klinik Psikofarmakoloji Bulteni

Volumn 19, Issue 1, 2009, Pages 29-38

  Saylan, Mete ^a,f   Ucok, Alp ^b   Uguz, Sükrü ^c   Treuer, Tamas ^d   Sir, Aytekin ^e  

^a ABBOTT LABORATORIES   (United States)

^b ISTANBUL UNIVERSITY   (Turkey)

^c CUKUROVA UNIVERSITY   (Turkey)

^d Lilly Hungaria Kft   (Hungary)

^e DICLE UNIVERSITY   (Turkey)

^f NONE   (Turkey)

Author keywords

Antipsychotic; Latent class analysis; Schizophrenia; Social class

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MENTAL DISEASE; OUTCOME ASSESSMENT; PSYCHOLOGIC ASSESSMENT; SCHIZOPHRENIA; SOCIAL CLASS; SOCIAL INTERACTION; TURKEY (REPUBLIC);

EID: 66849119274     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Jobe TH, Harrow M. Long-term outcome of patients with schizophrenia: a review. Can J Psychiatry 2005;50:892-900
2. Hafner H, an de Heiden W. Course and outcome of schizophrenia In: Hirsh SR, Weinberger DR, editors. Schizophrenia. London: Blackwell Science, Second Edition 2003: 101-131
3. WHO. ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research, WHO, Geneva, 1993
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR). Washington, DC: APA, 2000
5. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow- up. Am J Psychiatry 2005;162:495-506
6. Kurtz MM, Moberg PJ, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull 2005;31:167-174
7. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 1991;48:239-246
8. Weisman AG. Understanding cross-cultural prognostic variability for schizophrenia. Cult Divers Ment Health 1997;3:23-35
9. Sartorius N, Jablensky A, Shapiro R. Cross-cultural differences in the short-term prognosis of schizophrenic psychoses. Schizophr Bull 1978;4:102-113
10. Cancro R. Lehmann HE. Schizophrenia: Clinical Features. In: Kaplan&Sadock's Comprehensive Textbook of Psychiatry, seventh edition, volume 1. Williams and Wilkins, Philadelphia, USA, 2000:1169-1199
11. Händel M, Bailer J, Bräuer W, Laubenstein D, Rey ER. The Prognostic Scale by Strauss and Carpenter and its validity. Eur Arch Psychiatry Clin Neurosci 1996;246:203-208
12. Hafner H, an der Heiden W. The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci 1999;249 (Suppl 4):14-26
13. Leff JP. Care in the community: illusion or reality? John Wiley&Sons, Chichester, 1997
14. Lewine RR. Social class of origin, lost potential, and hopelessness in schizophrenia. Schizophr Res 2005; 15;76:329-335
15. Browne G, Courtney M. Measuring the impact of housing on people with schizophrenia. Nurs Health Sci 2004; 6:37-44
16. Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsiao JK, Lieberman J; CATIE Study Investigators Group. Barriers to employment for people with schizophrenia. Am J Psychiatry. 2006;163:411-7
17. Cooper B. Schizophrenia, social class and immigrant status: the epidemiological evidence. Epidemiol Psichiatr Soc 2005;14:137-144
18. Curtis S, Copeland A, Fagg J, Congdon P, Almog M, Fitzpatrick J. The ecological relationship between deprivation, social isolation and rates of hospital admission for acute psychiatric care: a comparison of London and New York City. Health Place 2006;12:19-37
19. Lanza ST, Collins LM, Schafer JL, Flaherty BP. Using data augmentation to obtain standard errors and conduct hypothesis tests in latent class and latent transition analysis. Psychol Methods. 2005;10:84-100
20. McLachlan, G.J, Basford, K.E. Mixture Models: Inference and Applications to Clustering. New York, NY: Marcel Dekker, 1988
21. Fossati A, Maffei C, Battaglia M, Bagnato M, Donati D, Donini M, Fiorilli M, Novella L. Latent class analysis of DSM-IV schizotypal personality disorder criteria in psychiatric patients. Schizophr Bull 2001;27:59-71
22. Peralta V, Cuesta MJ. The nosology of psychotic disorders: a comparison among competing classification systems. Schizophr Bull 2003;29:413-425
23. van Lang ND, Ferdinand RF, Ormel J, Verhulst FC.Latent class analysis of anxiety and depressive symptoms of the Youth Self- Report in a general population sample of young adolescents. Behav Res Ther 2006 ;44:849-860
24. Young MA, Scheftner WA, Klerman GL, Andreasen NC, Hirschfeld RM. The endogenous sub-type of depression: a study of its internal construct validity.Br J Psychiatry 1986;148:257-267
25. Bollen KA. Latent variables in psychology and social sciences. Annu Rev. Psychol. 2002; 53;605-634
26. Dewa CS, Remington G, Herrmann N, Fearnley J, Goering P. How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience. Clin Ther 2002; 24:1466-1476
27. Trifiro G, Spina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur J Clin Pharmacol 2005; 61: 47-53
28. Kelly DL, Dixon LB, Kreyenbuhl JA, Medoff D, Lehman AF, Love RC, Brown CH, Conley RR. Clozapine utilization and outcomes by race in a public mental health system: 1994-2000. J Clin Psychiatry 2006 ;67:1404-1411
29. Mallinger JB, Fisher SG, Brown T, Lamberti JS. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv 2006;57:133-136
30. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept. Health, Education, and Welfare Publication (ADM) 76-388. Rockville Md: National Institute of Mental Health. 1976: 218-22
31. Vermunt JK. LEM 1.0: A general program for the analysis of categorical data. Tilburg: Tilburg University 1997
32. Chan Y, Walmsley RP. Learning and understanding the Kruskal- Wallis one-way analysis-of-variance-by-ranks test for differences among three or more independent groups. Phys Ther 1997;77:1755-1762
33. Lieberman JA, Malaspina D, Jarskog LF. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. CNS Spectr 2006;11: 14-15
34. Edgell ET, Croudace TJ, Jones PB, Haro JM. Statistical models for population heterogeneity in epidemiological longitudinal studies: Person centred latent class analysis to identify casemix groups in the Schizophrenia Outpatient Health Outcomes Study. European Neuropsychopharmacology 2002; 12:314
35. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V; Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine. Department of Veterans Affairs Cooperative Study Group on the Cost- Effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; ;290: 2693-2702
36. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-1028
37. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159: 255-262
38. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610
39. Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I; IC-SOHO Study Group. Effectiveness of antipsychotic treatments for schizophrenia-analysis from a prospective observational study (ICSOHO) comparing olanzapine, quetiapine, risperidone and haloperidol. J Clin Psychiatry 2004;65:312-21
40. McCutcheon AL. Latent Class Analysis. Beverly Hills, Calif;Sage Publication;1987